The American people deserve the truth.
FDA, do you remember Covaxin? The traditional whole-virion vaccine that you forced to jump through every bureaucratic hoop, while you were fast-tracking mRNA boosters based on trials conducted on just 8 mice? You urged the company to seek approval through a U.S. BLA trial, and they did—spending over $100 million on a massive Phase 3 trial that yielded top-line data showing broad protection against all variants of concern. Yet, despite this, you never approved an alternative traditional vaccine option after they successfully navigated your obstacle course. Why? Because just months after those results were published, you changed the rules to block any vaccine built on the original virus. This effectively killed the market for traditional vaccines based on the whole coronavirus. Meanwhile, you rolled out the next set of mRNA boosters, designed to mimic just a tiny piece of the spike protein on a virus that’s famously studied for its high mutation rates.
It’s been four long years, and you still haven’t approved any competitor vaccines. The government collects royalties from mRNA sales, with companies like Moderna paying over $400 million in a single year. But those profits wouldn’t roll in from a traditional vaccine sale, would they? How has this financial entanglement influenced your decision-making during the pandemic?
Your job is to serve the public—to prioritize science and protect the American people. But you’ve failed in that duty. Instead, you’ve used taxpayer dollars to accelerate only the development of “vaccines” that you own patents on, blocking all competitor vaccines for over four years. Do you really think the American people will trust that this next round of mRNA boosters will finally work, after six previous rounds failed to deliver?
Your actions have severely damaged your credibility. Government entities should never receive kickbacks from the sales of drugs they’re responsible for approving. This is an egregious conflict of interest, and we’re living with the consequences. The amount of blood on your hands is staggering. Next-generation vaccines that have been proven to stop transmission are approved overseas, yet Americans have no choice but to take this mRNA snake oil.
This is the biggest scam our country has ever seen. It’s time for real journalism to uncover the truth. There must be accountability, and the American people deserve to know who the main perpetrators are.
Rest in peace to all those lost in this pandemic due to this corruption.
$OCGN amazing how these donkeys have gone on and on for months now, claiming to be long term shareholders from the COVID peak, obnoxiously spamming shareholders to vote no, with main focus on management compensation/Shankar’s awards.
You would think a real investor, let alone a 6 year holder, would have mentioned back then or knew by now that shareholders voted on management’s compensation only awarded after milestones are met back in June this year, just like they have every single year since the company went public…😂🫏💀
Anyways, the vote will pass in December, flipping our books to bullish, along with Bahamas full approval and our first commercial patient being dosed.
Goodbye to the days of absurdities and the clowns that know absolutely nothing at all about the company spamming the board, hello to the days of revenue and growth.🍻👇
@KhalidBoAhmad@MoreFlax In 3-4 years with them having OCU400/410/410ST on the market, that’s a four digit stock, easily.
OCU410 alone they plan to dose 100k patients a year in US/EU, that is $25-$35 Billion in revenue yearly off one drug.🍻
$OCGN is targeting some of the biggest markets in biotech, with remarkable efficacy, a exceptional safety profile, hundreds of genetic mutations addressed with a single therapy, markets with little to no effective treatment options, a platform set to keep expanding with back to back pivotal results and commercialization right around the corner.
The markets are what they are, the numbers are what they are. Hell, I was breaking down these drugs numbers years ago showcasing the trillion dollar market potential you’re now seeing presented on the company’s slides.
My point is, if you’re buying this stock today, you’re buying what is clearly going to become one of the largest and most profitable biotech companies in history, before everyone else realizes it.
If you’ve ever wondered what it would’ve been like to buy into one of the giants of an industry at the ground floor, right before the steady rise to market leaders, well, you’re looking at one of those opportunities right now. It’s beyond obvious. 🍻
$ocgn Most will see “Phase 3 for GA in 2026” and shrug. The ones who know GA, the therapy and this market understand the gravity of what was just announced.
Dr. Jay Chhablan the Vice Chair of Clinical Trials at the University of Pittsburgh Medical Center Vision Institute just said the 6 month OCU410 data already looks superior to the FDA approved drugs when he compared them side by side.
Retail needs to understand why this sets OCU410 up as one of the most valuable medicines ever lined up to hit the market.
Why I’m saying that
OCU400 family keeps winning. OCU400 for IRDs, OCU410ST for Stargardt, and OCU410 for GA have shown consistent 100% efficacy signals with 100% safety to date. FDA’s recent CGT flexibility on self controlled designs external controls and registry follow up is also built for this platform and means a very fast path to market than anyone expects.
So why would OCU410 likely be the world’s most valuable drug and why has big pharma paid billions for early phase GA assets?
Because the numbers are staggering.
👇🍻💸🏦
Today, at the @Stifel 2026 Healthcare Conference, Ocugen CEO @drsmusunuri highlighted our novel modifier #genetherapy platform and three Phase 3 investigational assets in NYC. #Biotech
Watch the replay: https://t.co/SCtAn2pIX9
$OCGN
$OCGN People see that Celairis isn’t a giant, lacks doctors or labs, and assume they can’t do anything.
Reality is, a guy with RP walks into an ophthalmology office, doc says there’s an approved treatment, and he goes to a local surgeon to get dosed.
These aren’t development partnerships, they’re licensing deals. Ocugen retains control/sole manufacturing rights. Celairis gets OCU400 approved in their territory.
The question isn’t whether Celairis can manufacture or perform surgery. It’s whether they can get us approved.
Their CEO spent 11 years at Novartis as Country President for Australia/New Zealand, then ran Australia’s largest pharma company. I’d say he’s exactly who we need.
Ocugen isn’t selling out to BP. They know what they own, have commercial supply ready, and their drug uses existing surgical techniques.
The outcome is thousands of million dollar checks coming in globally for Ocugen to collect for the next 10+ years. 🍻
@Onderkilinc507 Yeah their partner Roots Pharmaceutical should have rights to that region. Potentially people in Turkey could see OCU400 in late 2027 with 2028 being a more realistic timeline. 🍻
CEO has 20 years of Biotech leadership, mostly from Novartis.
People tend to think of it like Celairis isn't a giant, they don’t have a bunch of doctors or labs and therefore won't be able to do anything.
Reality is, a guy with RP walks into an Ophthalmology office, doc says there's only one drug approved to treat it, and then they get dosed at their local surgeon.
These are not development partnerships, these are straight licensing deals where Ocugen maintains the control. We don’t need to sell our to BP, our drug works with the infrastructure countries already have and is delivered the same way people are already getting dosed. 🍻
$OCGN once again expanded its global reach while retaining a significant share of future profits. 50% of gross profits plus royalties. The company is set up to collect checks in the mail to the tune of billions yearly. 🍻
$OCGN If it isn’t painfully obvious by now, all the doom and gloom narratives constantly spread about this company always ends up fading into irrelevance. And it’s because the science here always speaks louder than the noise, and it’s screaming the next big pharma.
Fuck fuck fuck the noise, fam. 🍻
$OCGN We’re talking about a pre Rev biotech that’s just months away from pivotal results. If you bought this stock but didn’t buy it for the catalyst, then what exactly were you buying it for, and why have you held this whole time?
Over the past year, the stock has ranged from $0.70-$2.50. If SP was your whole reason for buying, could’ve sold at $2.50. But if you actually bet on the products, then buck up buttercup. The current price range is about to be completely irrelevant.
Examples of pre rev biotechs heading into pivotal Phase 3 results:
1. ABVX (2025)
Bled 72% before Phase 3 results.
Then went from $4.77 to $148.83.
2. CPXX (2016)
Bled 64% before Phase 3 results.
Then went from $1.12 to $30.36.
3. CELC (2025)
Bled 66% before Phase 3 results.
Then went from $7.58 to $120.32.
If this platform validates itself the way the evidence increasingly suggests it will, we’re talking about a market opportunity that makes all those examples look insignificant. 🍻
$OCGN The drugs are everything, and nearly every single piece of evidence we see suggests the trials are going damn well. Hearing patient after patient describe their improvements, and now over a year after treatment hearing them say they’re still seeing improvements, is exactly what an investor wants to see with phase 3 results just months away.
If this is the norm for people in the trial/EAP, the results will be beyond stellar and well beyond what’s needed to meet the primary endpoint. We’re going from having money riding on a speculative biotech to owning a piece of the next big pharma. 🍻
Ocugen is taking part in two key industry events this November!
CEO @drsmusunuri will participate in the Stifel 2026 Healthcare Conference and Cell & Gene Leaders Live 2026. Read more: https://t.co/Y5uVTzDX59
#HealthcareInnovation#GeneTherapy $OCGN
Today, FDA kicked off its Rare Disease Framework Initiative with a public meeting, co-hosted by @ReaganUdall. Thanks to all who joined for your input, candor & vision. With only 5% of rare diseases having an approved treatment, the status quo isn't enough — we must do more.
FDA Acting Commissioner @FDA_KyleD shared with the attendees that the “urgency of the need has not changed, but now we — the agency, drug developers, researchers, and patients — are ready to meet that need together.”